2004 NOV 2 - (NewsRx.com & NewsRx.net) -- Stellar Biotechnologies, Inc. has been awarded $3 million from the National Cancer Institute of the [U.S.] National Institutes of Health for the development of production methods, quality standards, and facilities for the commercialization of keyhole limpet hemocyanin (KLH) for use in anti-cancer vaccines.
The award is a competing continuation of a Small Business Innovative Research (SBIR) phase 2 grant previously awarded to the company for the development of aquaculture technology for Megathura crenulata (the source animal for KLH) and is funded through the NCI's FLAIR (Flexible System to Advance Innovative Research) program …
No comments:
Post a Comment